Literature DB >> 10440686

Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis.

K Tarao1, Y Rino, S Ohkawa, A Shimizu, S Tamai, K Miyakawa, H Aoki, T Imada, K Shindo, N Okamoto, S Totsuka.   

Abstract

BACKGROUND: Many studies have demonstrated in animal experiments that persistent inflammation may accelerate the development of carcinoma. In this article, the question of whether the persistent elevation of serum alanine aminotransferase (ALT) levels (which represents the inflammatory necrosis of hepatocytes) correlates with the development of hepatocellular carcinoma (HCC) was studied in patients with early stage hepatitis C virus (HCV)-associated cirrhosis.
METHODS: Sixty-nine consecutive patients with biopsy proven HCV-associated cirrhosis (mostly Child's Stage A) who had been followed for >5 years for the development of HCC were studied. They were subdivided into 3 groups according to their serum ALT levels: Group A was comprised of 28 patients whose annual average serum ALT level was persistently high (>/= 80 IU) (high ALT group), Group B was comprised of 28 patients whose annual average serum ALT level was persistently low (< 80 IU) (low ALT group), and Group C was comprised of 13 unclassified patients. The patients had been studied prospectively with frequent ultrasonography and magnetic resonance imaging or computed tomography for > 5 years.
RESULTS: In the high ALT group HCC developed in 71.4% of patients compared with 25.0% in the low ALT group over the observation period (P < 0.005). The 5-year rate of incidence of HCC in the high ALT group was as high as 53.6% compared with only 7.1% in the low ALT group (P < 0.001). The expected interval between the diagnosis of cirrhosis and the development of HCC was 6.0 +/- 0.7 years (mean +/- standard error) in the high ALT group and 12.7 +/- 1.2 years in the low ALT group (P < 0.001).
CONCLUSIONS: The results of the current study demonstrated that the development of HCC was more rapid in the high ALT group with HCV-associated cirrhosis. Copyright 1999 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10440686     DOI: 10.1002/(sici)1097-0142(19990815)86:4<589::aid-cncr7>3.0.co;2-k

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  40 in total

1.  The TNF-α, IL-1B and IL-10 polymorphisms and risk for hepatocellular carcinoma: a meta-analysis.

Authors:  Yu Yang; Chao Luo; R Feng; Sheng Bi
Journal:  J Cancer Res Clin Oncol       Date:  2010-11-24       Impact factor: 4.553

2.  Relation between incidence of hepatic carcinogenesis and integration value of alanine aminotransferase in patients with hepatitis C virus infection.

Authors:  Takashi Kumada; Hidenori Toyoda; Seiki Kiriyama; Yasuhiro Sone; Makoto Tanikawa; Yasuhiro Hisanaga; Akira Kanamori; Junji Kondo; Takahiro Yamauchi; Satoshi Nakano
Journal:  Gut       Date:  2007-05       Impact factor: 23.059

Review 3.  Hepatocellular carcinoma--cause, treatment and metastasis.

Authors:  Z Y Tang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

4.  Risk factors for the recurrence of hepatocellular carcinoma after radiofrequency ablation of hepatocellular carcinoma in patients with hepatitis C.

Authors:  Yutaka Yamanaka; Katsuya Shiraki; Kazumi Miyashita; Tomoko Inoue; Tomoyuki Kawakita; Yumi Yamaguchi; Yukiko Saitou; Norihiko Yamamoto; Takeshi Nakano; Atsuhiro Nakatsuka; Koichiro Yamakado; Kan Takeda
Journal:  World J Gastroenterol       Date:  2005-04-14       Impact factor: 5.742

5.  Integrated fibrosis scoring by ultrasonography predicts the occurrence of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.

Authors:  Tetsuya Nishiura; Hideaki Watanabe; Koji Yano; Masahiro Ito; Seigo Abiru; Toshifumi Fujimoto; Atsumasa Komori; Hiroshi Yatsuhashi; Yojiro Matsuoka; Hiromi Ishibashi
Journal:  J Med Ultrason (2001)       Date:  2010-10-20       Impact factor: 1.314

6.  Hepatitis C virus and its roles in cell proliferation.

Authors:  Kunitada Shimotohno; Koichi Watashi; Katsuya Tsuchihara; Katsuhiko Fukuda; Hiroyuki Marusawa; Makoto Hijikata
Journal:  J Gastroenterol       Date:  2002       Impact factor: 7.527

7.  Influence of age, sex, and degree of liver fibrosis on the association between serum alanine aminotransferase levels and liver inflammation in patients with chronic hepatitis C.

Authors:  Hidenori Toyoda; Takashi Kumada; Seiki Kiriyama; Yasuhiro Sone; Makoto Tanikawa; Yasuhiro Hisanaga; Kazuhiko Hayashi; Takashi Honda; Teiji Kuzuya
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

8.  Significance of prior hepatitis B virus infection in the development of hepatocellular carcinoma in patients with chronic hepatitis C.

Authors:  Fumio Imazeki; Osamu Yokosuka; Kenichi Fukai; Akira Hiraide; Hiromitsu Saisho
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

9.  Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation.

Authors:  Min-Jie Ju; Shuang-Jian Qiu; Jia Fan; Jian Zhou; Qiang Gao; Ming-Yan Cai; Yi-Wei Li; Zhao-You Tang
Journal:  J Gastroenterol       Date:  2009-04-22       Impact factor: 7.527

10.  Efficacy of MK615 for the treatment of patients with liver disorders.

Authors:  Atsushi Hokari; Tomohisa Ishikawa; Hisao Tajiri; Takahide Matsuda; Osamu Ishii; Nobuyuki Matsumoto; Chiaki Okuse; Hideaki Takahashi; Takeshi Kurihara; Ko-Ichi Kawahara; Ikuro Maruyama; Mikio Zeniya
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.